Clinical Trial Update: A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update for migalastat in pediatric subjects aged 2 to under 12 with Fabry disease and amenable GLA variants. The study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Migalastat (migalastat)

Snippet

Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 3 | Status: RECRUITING